EGFR and colorectal carcinoma: International guidelines from NCCN, ASCO, and the European Medicines Evaluation Agency recommend that advanced CRC patients undergo KRAS mutation testing since anti-EGFR therapies such as cetuximab and panitumumab are effective only in patients with wild-type KRAS [39,40]